The scientists’ findings suggest that using a structure-based vaccine design and self-assembling nanoparticles to deliver a viral protein that prompts an immune response could be a promising approach for developing an EBV vaccine for humans.
M Kanekiyo et al. Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor Binding Site. Cell DOI: 10.1016/j.cell.2015.07.043 (2015).
NIAID director Anthony S. Fauci, M.D., and Jeffrey Cohen, M.D., chief of NIAID’s Laboratory of Infectious Diseases and co-corresponding author on the study, are available to comment.
To schedule interviews, please contact Emily Mullin, (301) 402-1663, email@example.com.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health ®